Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 2
1986 4
1987 1
1988 6
1989 4
1990 5
1991 10
1992 10
1993 16
1994 12
1995 16
1996 20
1997 14
1998 24
1999 39
2000 48
2001 56
2002 46
2003 60
2004 41
2005 62
2006 53
2007 52
2008 55
2009 53
2010 44
2011 37
2012 44
2013 48
2014 37
2015 47
2016 45
2017 33
2018 24
2019 42
2020 37
2021 38
2022 23
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

1,134 results
Results by year
Filters applied: . Clear all
Page 1
Chemoprevention or mastectomy for women at high risk of developing breast cancer.
Sismondi P, D'Alonzo M, Pecchio S, Bounous VE, Robba E, Biglia N. Sismondi P, et al. Maturitas. 2015 Nov;82(3):271-3. doi: 10.1016/j.maturitas.2015.07.002. Epub 2015 Jul 26. Maturitas. 2015. PMID: 26276104 Review.
Many factors, both genetic and non-genetic, determine a woman's risk of breast cancer and several mathematical models have been proposed that determine the risk. ...Risk-reduction agents are recommended for women aged 35 yea …
Many factors, both genetic and non-genetic, determine a woman's risk of breast cancer and several mathema …
Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients.
Gilman EA, Pruthi S, Hofstatter EW, Mussallem DM. Gilman EA, et al. Mayo Clin Proc. 2021 Apr;96(4):1033-1040. doi: 10.1016/j.mayocp.2021.01.028. Mayo Clin Proc. 2021. PMID: 33814072 Review.
For certain women at high risk for breast cancer, endocrine therapy (ET) can greatly decrease the risk. Tools such as the Breast Cancer Risk Assessment Tool (or Gail Model) and the International Breast Cance …
For certain women at high risk for breast cancer, endocrine therapy (ET) can greatly decrease the risk …
Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT, Willson ML, Goel S, Beith J, Goodwin A. Bui KT, et al. Cochrane Database Syst Rev. 2020 Mar 6;3(3):CD013538. doi: 10.1002/14651858.CD013538. Cochrane Database Syst Rev. 2020. PMID: 32141074 Free PMC article.
SELECTION CRITERIA: We included all randomised trials assessing any method of OFS, that is, oophorectomy, radiation-induced ovarian ablation, or LHRH agonists, as adjuvant treatment for premenopausal women with early-stage breast cancer. We included studies t …
SELECTION CRITERIA: We included all randomised trials assessing any method of OFS, that is, oophorectomy, radiation-induced ovarian ablation …
Patient and provider factors associated with the noninitiation of tamoxifen for young women at high-risk for the development of breast cancer.
Kandagatla P, Rizk NN, Dokic D, Kochkodan J, Estevez S, Yanik M, Goranta S, Huber-Keener K, Jeruss JS. Kandagatla P, et al. Breast J. 2020 Mar;26(3):464-468. doi: 10.1111/tbj.13528. Epub 2019 Sep 20. Breast J. 2020. PMID: 31538708 Free article.
We sought to identify factors associated with disparities in tamoxifen utilization among young patients at high-risk for developing breast cancer. We identified 67 premenopausal, high-risk women age 35-45, without surgical p …
We sought to identify factors associated with disparities in tamoxifen utilization among young patients at high-risk fo …
Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.
Atakpa EC, Thorat MA, Cuzick J, Brentnall AR. Atakpa EC, et al. Cochrane Database Syst Rev. 2021 Oct 26;10(10):CD013091. doi: 10.1002/14651858.CD013091.pub2. Cochrane Database Syst Rev. 2021. PMID: 34697802 Free PMC article. Review.
OBJECTIVES: To assess the evidence that a reduction in mammographic density following endocrine therapy for breast cancer prevention in women without previous breast cancer, or for treatment in women with early-stage hormone receptor-posi …
OBJECTIVES: To assess the evidence that a reduction in mammographic density following endocrine therapy for breast cancer prev …
Tamoxifen: a most unlikely pioneering medicine.
Jordan VC. Jordan VC. Nat Rev Drug Discov. 2003 Mar;2(3):205-13. doi: 10.1038/nrd1031. Nat Rev Drug Discov. 2003. PMID: 12612646 Review.
For more than 25 years, tamoxifen has been the gold standard for the endocrine treatment of all stages of oestrogen-receptor-positive breast cancer, and the World Health Organization lists tamoxifen as an essential drug for the treatment of breast …
For more than 25 years, tamoxifen has been the gold standard for the endocrine treatment of all stages of oestrogen-receptor-positive …
Chemoprevention of breast cancer for women at high risk.
Chan K, Morris GJ. Chan K, et al. Semin Oncol. 2006 Dec;33(6):642-6. doi: 10.1053/j.seminoncol.2006.08.017. Semin Oncol. 2006. PMID: 17145342 Review.
Several studies have identified cohorts of women at higher than average risk to develop this disease. These are women who are exposed to high levels of endogenous or exogenous estrogens, those with a family history of breast cancer, and t …
Several studies have identified cohorts of women at higher than average risk to develop this disease. These are women w …
Risk Factors for Tamoxifen-Induced Ovarian Hyperstimulation in Breast Cancer Patients.
Kim MK, Shin HC. Kim MK, et al. Clin Breast Cancer. 2020 Oct;20(5):408-412. doi: 10.1016/j.clbc.2020.01.003. Epub 2020 Jan 28. Clin Breast Cancer. 2020. PMID: 32727665
INTRODUCTION: Adjuvant endocrine therapy is an integral component of care for hormone-dependent breast cancer. Tamoxifen is a potent inducer of ovarian function and consequent hyperestrogenism in premenopausal women. However, the incidence rate and …
INTRODUCTION: Adjuvant endocrine therapy is an integral component of care for hormone-dependent breast cancer. Tamoxifen …
What Factors Influence Decision-Making about Breast Cancer Chemoprevention among High-Risk Women?
Crew KD. Crew KD. Cancer Prev Res (Phila). 2017 Nov;10(11):609-611. doi: 10.1158/1940-6207.CAPR-17-0281. Epub 2017 Oct 4. Cancer Prev Res (Phila). 2017. PMID: 28978567 Free PMC article.
Estrogen exposure is one of the strongest risk factors for breast cancer development. Chemoprevention with selective estrogen receptor modulators (SERM), such as tamoxifen and raloxifene, has been shown in randomized controlled trials to reduce brea …
Estrogen exposure is one of the strongest risk factors for breast cancer development. Chemoprevention with selective es …
Clinical options for women at high risk for breast cancer.
Hartmann LC, Sellers TA, Schaid DJ, Nayfield S, Grant CS, Bjoraker JA, Woods J, Couch F. Hartmann LC, et al. Surg Clin North Am. 1999 Oct;79(5):1189-206. doi: 10.1016/s0039-6109(05)70068-2. Surg Clin North Am. 1999. PMID: 10572558 Review.
Women at hereditary risk of breast cancer face a difficult clinical decision. ...It is generally believed that women significantly overestimate their risk of breast cancer. Thus, it is vital that a woman at risk …
Women at hereditary risk of breast cancer face a difficult clinical decision. ...It is generally believed that …
1,134 results